Variant position: 60 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 189 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human YRKQVVIDGETCLLDILDTA GQEEYSAMRDQYMRTGEGFLC
Mouse YRKQVVIDGETCLLDILDTA GQEEYSAMRDQYMRTGEGFLC
Rat YRKQVVIDGETCLLDILDTA GQEEYSAMRDQYMRTGEGFLC
Xenopus laevis YRKQVVIDGETCLLDILDTA GQEEYSAMRDQYMRTGEGFLC
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 186 GTPase KRas
2 – 186 GTPase KRas, N-terminally processed
59 – 60 GTP
60 – 62
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.
Niihori T.; Aoki Y.; Narumi Y.; Neri G.; Cave H.; Verloes A.; Okamoto N.; Hennekam R.C.M.; Gillessen-Kaesbach G.; Wieczorek D.; Kavamura M.I.; Kurosawa K.; Ohashi H.; Wilson L.; Heron D.; Bonneau D.; Corona G.; Kaname T.; Naritomi K.; Baumann C.; Matsumoto N.; Kato K.; Kure S.; Matsubara Y.;
Nat. Genet. 38:294-296(2006)
Cited for: VARIANT CFC2 ARG-60;
Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.
Gremer L.; Merbitz-Zahradnik T.; Dvorsky R.; Cirstea I.C.; Kratz C.P.; Zenker M.; Wittinghofer A.; Ahmadian M.R.;
Hum. Mutat. 32:33-43(2011)
Cited for: CHARACTERIZATION OF VARIANTS NS3 ILE-14; ARG-22; LEU-34; ILE-58 AND VAL-153 (ISOFORM 2); CHARACTERIZATION OF VARIANTS CFC2 GLU-22; ARG-34 AND ARG-60; CHARACTERIZATION OF VARIANTS ASN-5 AND LEU-156 (ISOFORM 2); FUNCTION; CATALYTIC ACTIVITY;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.